Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00544739
Other study ID # 2 P05B 013 28
Secondary ID
Status Completed
Phase N/A
First received October 15, 2007
Last updated January 16, 2012
Start date April 2005
Est. completion date September 2010

Study information

Verified date January 2012
Source Institute of Cardiology, Warsaw, Poland
Contact n/a
Is FDA regulated No
Health authority Poland: Ministry of Science and Higher Education
Study type Observational

Clinical Trial Summary

Cardiovascular risk in women is systematically underestimated by both - society and physicians. Women younger than 50 years of age with acute coronary syndrome have 2x higher mortality compared with age-matched men. A number of common vascular-disease-related conditions are more frequent in women than in men. Women develop a more severe or different form of vascular disease then men. Variability of onset, relative risk, and the synergy of traditional and novel risk factors creates a challenge to physicians possibly resulting in suboptimal management and disregard in women presenting with angina symptoms.

During last 10 years the rise in coronary artery disease (CAD) prevalence in younger women is observed. Emerging data suggest a unique risk profile in women (hypoestrogenemia with adverse effects of a protracted dysmetabolic state). The risk factors assessment and the risk factors profiles in women that are associated with CAD may be different than in men and thus merit reassessment.

Purpose The primary objective of this study is to determine characteristics and prognosis of women with premature coronary artery disease and to evaluate the extent of atherosclerosis


Description:

• Study Design Single-center, standardized, case-control study designed to assess the prevalence and significance of novel and traditional risk factors of premature coronary artery disease in women. Phase I (April 30th 2005- January 1st 2008) enrolled women with onset of symptomatic coronary artery disease before 55 years of age. The control group of 347 clinically healthy, age matched women was selected from the National Health Survey WOBASZ study (Polish Multicenter Population Study designed by Epidemiology and Cardiovascular Disease Prevention and Health Promotion Department of Institute of Cardiology) according to specifically designed questionnaire for WOBASZ study, and only subjects with negative history of CVD or negative exertional chest pain were included (Rywik S, Kupść W, Piotrowski W, et al. Wieloośrodkowe ogólnopolskie badanie stanu zdrowia ludności - projekt WOBASZ Założenia metodyczne oraz logistyka. Kardiol Pol 2005;63(supl.IV) 605:613).

Definition of premature CAD in women contained onset of coronary artery disease (myocardial infarction or coronary revascularization) before 55 years of age. Study participants are enrolled after coronary angiography and after identification and screening the age of admitted patients for acute coronary syndrome, stable angina or revascularization procedure. At the time of enrollment, participants give written informed consent for the study.

Information on demographic factors, social characterization, life style, education, anthropometric measurements, symptom characteristics and anamnesis, gynecologic history, family history on CVD and cancer, physical examination data, personal or family history of CVD, socioeconomic status, cardiovascular assessments and medication used was obtained through the use of a structured case report form questionnaire (CRF).

Additional fasting blood samples (15ml) are drawn from every individual (patients and controls) and frozen immediately at -70 for genetic study and in patients only half blood samples are centrifuged, separated, and frozen immediately at -70o after processing.

Baseline evaluation consisted of CRF data, and collection of coronary angiography, carotid ultrasonography and laboratory data.

The study protocol is approved by the Institutional Review Boards and Local Bioethics Committee.

- Follow-up All patients are contacted at 6 months after discharge from the hospital, and then every 6 months, for at least 4 years, to assess symptom status, menstrual status and occurrence of cardiovascular events (MACE) including death, nonfatal myocardial infarction, coronary revascularization, cardiac surgery and hospitalization for unstable angina.

- Study Endpoints

Primary Outcome Measures:

1. To evaluate the prevalence of atherosclerosis risk factors in women with premature CAD, including family history, social, environmental, clinical, traditional and novel risk factors, menopausal status and its association with early onset of the disease as compared to matched controls.

2. To evaluate the association of clinical factors to extent and advance of atherosclerosis

3. To evaluate predictive role of clinical factors and in particular: impaired fasting glucose, abdominal obesity, hypertension, metabolic syndrome, inflammatory markers, coexisting inflammatory and immunologic diseases on prognosis at 1 year and long-term follow-up in terms of MACE (cardiovascular death, nonfatal MI, revascularization, hospitalization due to heart failure III/IV or acute coronary syndrome)

Secondary Outcome Measures:

1. To evaluate predictive role of clinical factors and in particular: impaired fasting glucose, abdominal obesity, hypertension, metabolic syndrome, inflammatory markers, coexisting inflammatory and immunologic diseases on prognosis in terms of Vascular Events (MACE, hospitalization due to CAD progression, major arrhythmia, with ICD implantation, and stroke)

2. To evaluate predictive role of clinical factors and in particular: impaired fasting glucose, abdominal obesity, hypertension, metabolic syndrome, inflammatory markers, coexisting inflammatory and immunologic diseases on prognosis in terms of components of Vascular Events and total mortality

Endpoints assessment:

Independent endpoint classification committee comprising of 2 not involved into study procedures cardiologists will review documentation of the event and classify it.

The study may have significant implications for improvement, identification and management of female patients at risk of premature atherosclerosis providing more gender-specific data for efficacy and safety of cardiovascular medication. Better scientific recognition will result in better awareness of risk and effective prevention of coronary artery disease in young females, in optimizing the delivery of heart care to population of young women and rationale for guidelines specific for women.


Recruitment information / eligibility

Status Completed
Enrollment 670
Est. completion date September 2010
Est. primary completion date June 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Patients: Consecutive women with onset of evident CAD before 55 years of age (admitted to coronary angiography because of acute coronary syndrome, stable angina or revascularization procedure)

- agreement to participate the study

- Controls : age-matched healthy women selected from participants examined between 2004-2006 in the National Health Survey - WOBASZ study with negative history of exertional chest pain, angina, hospitalization of revascularization procedures or coronary treatment.

Exclusion Criteria:

- inability to give informed consent death before discharge during the index hospitalization

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Locations

Country Name City State
Poland Institute of Cardiology, Warsaw

Sponsors (1)

Lead Sponsor Collaborator
Institute of Cardiology, Warsaw, Poland

Country where clinical trial is conducted

Poland, 

References & Publications (2)

Lubiszewska B, Kruk M, Broda G, Ksiezycka E, Piotrowski W, Kurjata P, Zielinski T, Ploski R. The impact of early menopause on risk of coronary artery disease (PREmature Coronary Artery Disease In Women--PRECADIW case-control study). Eur J Prev Cardiol. 20 — View Citation

Lubiszewska B, Skóra E, Kruk M, Broda G, Ksiezycka E, Kurjata P, Zielinski T, Ploski R. Prevalence of classical risk factors in Polish women with premature coronary artery disease. Kardiol Pol. 2010 Sep;68(9):1032-7. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of clinical characteristics between study group and matched controls 1-year (short-term), 4-year (long-term) No
Primary Association of clinical factors to extent and advance of atherosclerosis 1-year (short-term), 4-year (long-term) No
Primary Predictive role of clinical factors on prognosis in terms of MACE 1-year (short-term), 4-year (long-term) No
Secondary Predictive role of clinical factors on prognosis in terms of Vascular Events 1-year, 2-year, 3-year, 4-year No
Secondary Predictive role of clinical factors on prognosis in terms of components of Vascular Events and total mortality 1-year, 2-year, 3-year, 4-year No
See also
  Status Clinical Trial Phase
Completed NCT02335086 - DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease N/A
Withdrawn NCT02265146 - ORACLE-NIRS: Lipid cORe Plaque Association With CLinical Events: a Near-InfraRed Spectroscopy Study
Completed NCT00811772 - Trial of Drug Eluting Stent Versus Bare Metal Stent to Treat Coronary Artery Stenosis N/A
Recruiting NCT03322332 - Adipokines of Epicardial Adipose Tissue and Atherosclerosis of Coronary Arteries N/A
Completed NCT02305953 - Cytokines and Vascular Inflammation in Psoriasis N/A
Completed NCT01642173 - Assessment of Coronary Plaque Composition Using Optical Coherence Tomography Phase 1
Completed NCT02316782 - Bifurcation Lesion Analysis and STenting / BLAST
Completed NCT00548613 - Combination Stem Cell (MESENDO) Therapy for Utilization and Rescue of Infarcted Myocardium Phase 1
Terminated NCT00243308 - Serp-1 for the Treatment of Acute Coronary Syndrome Phase 2
Recruiting NCT05105750 - A Comparative Study of Indobufen and Aspirin in Patients With Coronary Atherosclerosis Phase 4
Completed NCT01722214 - Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis Phase 4
Terminated NCT01030328 - AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis Phase 3
Suspended NCT00790764 - Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI) Phase 2
Active, not recruiting NCT01061398 - CT-FIRST: Cardiac Computed Tomography Versus Stress Imaging For Initial Risk STratification N/A
Completed NCT00431717 - Coronary Computed Tomography Angiography and SPECT in Asymptomatic Diabetes N/A
Completed NCT00431977 - Validation Study of Coronary CT Angiography as a Screening Tool in Asymptomatic Diabetes N/A
Recruiting NCT00155350 - Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients Phase 4
Recruiting NCT05708547 - Role of Mitophagy in Myeloid Cells During Coronary Atherosclerosis.
Terminated NCT02440646 - Natural History of Coronary Atherosclerosis in Real-World Stable Chest Pain Patients Underwent Computed Tomography Angiography in Comparison With Invasive Multimodality Imaging
Terminated NCT01268319 - CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow N/A